BioAtla Investor Presentation Deck

CAB-CTLA-4 (BA3071) Phase 2 Mono and Combo Study Currently Underway Study designed for multiple approval paths Treatment Refractory: melanoma carcinomas Monotherapy and Combination with PD1 bicatla Treatment Naïve (1st L): melanoma NSCLC Combination with PD1 350 mg Potential higher dose 350 mg Potential higher dose ● ● Monotherapy assessment Evaluating path for potential accelerated approval Further characterize safety and efficacy Inform path to pivotal RCT for full approval BioAtla| Overview 22

View entire presentation